Metabolomics Workbench : NIH Data Repository

Clustering data with hclust algorithm for (Study ST000669)

(Analysis AN001024)

Metabolite	Structure	F1	F2	F3	F4
IS PA 34:0 ;[M-H]-	ME183145	0.42	0.56	2.93	0.08
FFA(20:1)	ME183135	0.49	0.15	2.00	0.36
PC 42:4; [M-Ac-H]-@8.22	ME183187	0.62	0.04	1.99	0.37
CL 74:1; [M-2H](2-)@7.50	ME183123	0.40	0.24	2.06	0.25
FFA(22:1)	ME183138	0.38	0.28	1.98	0.38
PE 36:1; [M-H]-@7.50	ME183195	0.39	0.30	1.99	0.33
PC 31:0; [M-Ac-H]-@6.67	ME183153	0.19	0.38	1.99	0.45
PC 32:0; [M-Ac-H]-@6.91	ME183154	0.22	0.39	2.06	0.28
PG 38:3; [M-H]-@5.76	ME183217	0.24	0.45	1.98	0.35
PE 36:1; [M-H]-@5.84	ME183196	0.09	NA	1.93	0.04
PE 38:2; [M-H]-@7.57	ME183203	0.42	0.32	2.26	NA
FFA(20:2)	ME183136	0.27	0.06	2.19	0.30
PE 36:2; [M-H]-@5.42	ME183197	0.31	0.07	2.21	0.19
FFA(22:2)	ME183139	0.14	0.10	2.30	0.17
FFA(24:2)	ME183143	0.14	0.02	2.36	0.13
FFA(22:3)	ME183140	0.09	0.07	2.38	0.08
FFA(24:3)	ME183144	0.08	0.11	2.36	0.10
FFA(24:1)	ME183142	0.12	0.02	2.39	0.07
lysoPE 24:0; [M-H]-@5.28	ME183251	0.08	0.01	2.43	0.05
PG 36:2; [M-H]-@5.56	ME183215	0.01	0.27	2.24	0.24
Arachidonic acid	ME183120	0.13	0.25	2.25	0.11
PG 36:3; [M-H]-@5.13	ME183216	0.05	0.29	2.31	0.04
PE 40:5; [M-H]-@6.17	ME183209	0.69	0.15	1.58	NA
PC 42:5; [M-Ac-H]-@7.89	ME183188	1.02	0.06	1.70	0.53
CL 70:1; [M-2H](2-)@6.90	ME183121	1.01	0.31	1.67	0.34
PI 40:4; [M-H]-@6.16	ME183240	0.63	0.32	1.80	0.44
plasmenyl-PE 40:4; [M-H]-@7.79	ME183265	0.89	0.19	1.70	0.53
lysoPE 18:0; [M-H]-@2.50	ME183244	0.76	0.20	1.82	0.39
PE 34:1; [M-H]-@6.90	ME183191	0.82	0.19	1.78	0.44
PI 40:6; [M-H]-@5.63	ME183241	0.49	0.40	1.71	0.69
plasmenyl-PE 32:1; [M-H]-@6.66	ME183252	0.66	0.13	1.74	0.72
PI 36:3; [M-H]-@5.20	ME183234	0.71	0.44	1.49	0.87
FFA(24:0)	ME183141	0.79	0.45	1.59	0.58
plasmenyl-PE 40:5; [M-H]-@7.47	ME183266	0.70	0.50	1.63	0.53
CL 78:3; [M-2H](2-)@7.53	ME183126	0.90	0.35	1.57	0.61
plasmenyl-PE 34:1; [M-H]-@7.24	ME183253	0.80	0.28	1.64	0.64
CL 82:13; [M-2H](2-)@6.48	ME183129	0.31	1.43	1.39	0.47
PE 40:7; [M-H]-@6.41	ME183211	0.42	1.47	1.37	0.36
PC 32:1; [M-Ac-H]-@6.38	ME183155	0.58	0.94	1.45	0.57
PE 40:8; [M-H]-@6.02	ME183212	0.57	0.92	1.59	0.34
PC 34:1; [M-Ac-H]-@9.62	ME183161	NA	0.46	1.27	NA
PE 40:4; [M-H]-@7.45	ME183208	NA	0.73	1.14	NA
PE 32:0; [M-H]-@6.76	ME183189	0.16	1.22	1.68	0.27
PG 38:6; [M-H]-@4.69	ME183220	0.04	1.29	1.79	0.09
PG 44:10; [M-H]-@5.11	ME183226	0.02	1.20	1.85	0.09
PG 38:5; [M-H]-@5.09	ME183219	0.04	0.72	2.08	0.07
PG 38:4; [M-H]-@5.33	ME183218	0.04	0.75	2.09	0.02
PG 40:7; [M-H]-@4.98	ME183223	0.03	0.72	2.11	0.02
PG 40:8; [M-H]-@4.55	ME183224	0.06	0.72	2.11	0.00
PG 40:5; [M-H]-@5.47	ME183221	0.05	0.82	2.07	0.01
PG 40:6; [M-H]-@5.25	ME183222	0.09	0.84	2.02	0.03
PG 42:10; [M-H]-@4.48	ME183225	0.07	0.73	1.60	NA
PG 44:12; [M-H]-@4.34	ME183228	0.05	0.60	1.67	NA
PA 34:0; [M-H]-@6.77	ME183151	1.25	1.61	NA	0.14
PA 34:3; [M-H]-@0.69	ME183152	0.30	2.06	0.33	1.98
PG 36:0; [M-H]-@6.77	ME183214	0.41	1.37	NA	1.22
IS PI 37:4 ;[M-H]-	ME183149	0.62	1.96	0.74	0.95
PI 37:4; [M-H]-@5.39	ME183236	0.62	1.98	0.72	0.96
PE 40:6; [M-H]-@6.94	ME183210	0.61	1.89	0.90	0.70
PG 44:9; [M-H]-@5.30	ME183229	0.58	1.69	0.96	0.83
IS PS 34:0 ;[M-H]-	ME183150	0.61	1.47	1.03	0.87
PS 34:0; [M-H]-@6.19	ME183242	0.50	1.43	1.15	0.77
PC 34:0; [M-Ac-H]-@7.64	ME183159	0.86	1.49	0.86	0.94
IS PE 34:0 ;[M-H]-	ME183147	0.98	1.28	0.92	0.91
PE 34:0; [M-H]-@7.36	ME183190	0.97	1.29	0.91	0.92
CL 82:11; [M-2H](2-)@6.93	ME183128	0.48	2.42	0.83	0.44
PG 44:11; [M-H]-@4.76	ME183227	0.10	2.42	1.18	0.11
PC 33:2; [M-Ac-H]-@6.21	ME183158	2.00	0.05	0.97	NA
CL 70:3; [M-2H](2-)@6.51	ME183122	1.86	0.28	0.76	1.33
PC 37:4; [M-Ac-H]-@6.84	ME183176	1.75	0.23	0.88	1.26
PC 38:4; [M-Ac-H]-@7.04	ME183180	1.71	0.28	0.82	1.36
PC 38:4; [M-Ac-H]-@7.37	ME183179	1.71	0.28	0.82	1.36
PC 36:1; [M-Ac-H]-@7.71	ME183168	1.42	0.45	1.02	1.08
plasmenyl-PE 36:3; [M-H]-@6.99	ME183257	1.44	0.39	0.92	1.34
plasmenyl-PE 36:2; [M-H]-@7.40	ME183256	1.60	0.10	1.04	1.22
lysoPE 16:0; [M-H]-@1.69	ME183243	1.66	0.28	0.98	1.11
PC 35:4; [M-Ac-H]-@6.12	ME183167	1.50	0.27	1.00	1.22
PC 37:3; [M-Ac-H]-@6.98	ME183175	1.59	0.34	0.91	1.24
PC 36:6; [M-Ac-H]-@5.71	ME183174	1.62	0.76	0.48	1.67
PC 40:5; [M-Ac-H]-@7.29	ME183184	1.17	0.27	0.80	1.96
PE 34:3; [M-H]-@6.04	ME183193	1.26	0.20	0.88	1.78
PE 36:5; [M-H]-@6.03	ME183201	1.23	0.28	0.85	1.79
PC 38:3; [M-Ac-H]-@7.42	ME183178	1.45	0.18	0.77	1.83
PC 38:6; [M-Ac-H]-@6.28	ME183182	1.50	0.25	0.63	1.99
plasmenyl-PE 34:2; [M-H]-@6.80	ME183254	1.61	0.07	0.66	2.02
PC 36:2; [M-Ac-H]-@7.19	ME183169	1.73	0.16	0.72	1.67
PI 34:2; [M-H]-@5.09	ME183231	1.67	0.05	0.82	1.65
PE 34:2; [M-H]-@6.45	ME183192	1.85	0.29	0.64	1.57
PC 36:4; [M-Ac-H]-@6.33	ME183171	1.71	0.35	0.64	1.66
PC 36:4; [M-Ac-H]-@6.69	ME183172	1.71	0.35	0.64	1.66
PC 34:4; [M-Ac-H]-@5.80	ME183164	1.57	0.29	0.67	1.79
PC 38:5; [M-Ac-H]-@6.60	ME183181	1.63	0.33	0.65	1.75
lysoPE 18:1; [M-H]-@1.85	ME183245	2.46	0.08	0.73	1.01
lysoPE 20:3; [M-H]-@1.68	ME183247	2.23	0.62	0.51	1.13
lysoPE 20:4; [M-H]-@1.37	ME183248	2.83	0.05	0.24	1.64
lysoPE 22:6; [M-H]-@1.31	ME183250	2.67	0.12	0.19	1.82
PC 32:2; [M-Ac-H]-@5.85	ME183156	2.00	0.01	0.45	2.10
PC 34:2; [M-Ac-H]-@6.49	ME183162	2.03	0.19	0.47	1.84
PC 36:3; [M-Ac-H]-@6.67	ME183170	1.82	0.20	0.57	1.83
PC 34:3; [M-Ac-H]-@6.06	ME183163	2.32	0.04	0.42	1.79
PC 36:5; [M-Ac-H]-@5.89	ME183173	2.00	0.05	0.16	1.79
lysoPE 18:2; [M-H]-@1.40	ME183246	2.42	NA	0.14	1.31
lysoPE 22:5; [M-H]-@1.60	ME183249	1.95	NA	0.37	1.32
PC 35:2; [M-Ac-H]-@6.89	ME183166	2.08	0.08	0.34	1.50
plasmenyl-PE 42:6; [M-H]-@7.81	ME183268	0.86	0.04	1.14	1.96
PC 40:6; [M-Ac-H]-@7.00	ME183185	0.95	0.61	0.89	1.65
PE 37:4; [M-H]-@6.71	ME183202	0.77	0.62	0.94	1.73
PE 38:5; [M-H]-@6.53	ME183206	0.86	0.90	0.98	1.28
PC 40:7; [M-Ac-H]-@6.38	ME183186	1.03	0.68	1.07	1.16
CL 74:5; [M-2H](2-)@6.58	ME183124	1.15	0.58	1.00	1.27
PE 36:3; [M-H]-@6.59	ME183199	1.11	0.59	1.03	1.24
PE 36:0; [M-H]-@7.96	ME183194	0.41	0.72	1.32	1.24
PE 38:6; [M-H]-@6.31	ME183207	0.85	0.70	1.20	1.05
FFA(16:0)	ME183130	0.95	0.75	1.22	0.87
PI 38:4; [M-H]-@5.77	ME183238	0.83	0.65	1.31	0.89
PE 38:4; [M-H]-@7.04	ME183205	0.74	0.90	1.27	0.82
CL 78:5; [M-2H](2-)@7.28	ME183127	0.65	0.69	1.40	0.86
IS PG 34:0 ;[M-H]-	ME183148	0.70	0.71	1.38	0.84
PG 34:0; [M-H]-@6.22	ME183213	0.70	0.71	1.38	0.84
PE 38:3; [M-H]-@7.29	ME183204	0.67	0.78	1.39	0.78
FFA(22:0)	ME183137	0.72	0.71	1.40	0.77
PI 38:5; [M-H]-@5.22	ME183239	0.71	0.75	1.39	0.75
PI 34:1; [M-H]-@5.52	ME183230	0.91	1.05	1.23	0.59
CL 74:7; [M-2H](2-)@6.26	ME183125	1.11	0.85	1.02	1.00
PE 36:4; [M-H]-@6.31	ME183200	1.01	0.98	0.97	1.06
FFA(18:0)	ME183131	0.93	0.94	1.09	0.94
FFA(20:0)	ME183134	1.03	1.01	1.09	0.78
PI 36:4; [M-H]-@5.06	ME183235	1.10	0.95	1.04	0.86
plasmenyl-PE 38:2; [M-H]-@7.98	ME183260	0.56	0.02	1.54	1.32
FFA(18:2)	ME183133	1.54	0.09	1.20	0.96
plasmenyl-PE 36:1; [M-H]-@7.80	ME183255	1.51	0.11	1.25	0.87
FFA(18:1)	ME183132	1.22	0.20	1.34	0.91
plasmenyl-PE 38:5; [M-H]-@6.77	ME183263	1.14	0.20	1.38	0.90
PC 40:4; [M-Ac-H]-@7.70	ME183183	1.16	0.36	1.30	0.90
plasmenyl-PE 40:6; [M-H]-@7.25	ME183267	1.04	0.40	1.37	0.83
plasmenyl-PE 38:3; [M-H]-@7.60	ME183261	1.17	0.55	1.30	0.68
plasmenyl-PE 38:4; [M-H]-@7.31	ME183262	1.08	0.37	1.44	0.66
IS PC 34:0;[M-Ac-H]-	ME183146	1.24	0.07	1.20	1.30
PI 36:2; [M-H]-@5.75	ME183233	1.39	0.07	1.07	1.41
PI 36:1; [M-H]-@6.12	ME183232	1.19	0.01	1.33	1.13
plasmenyl-PE 36:5; [M-H]-@6.33	ME183259	0.91	0.10	1.37	1.24
PC 34:1; [M-Ac-H]-@7.00	ME183160	1.12	0.26	1.31	1.00
plasmenyl-PE 36:4; [M-H]-@6.74	ME183258	1.01	0.24	1.35	1.05
PC 38:2; [M-Ac-H]-@7.86	ME183177	1.05	0.23	1.31	1.10
PE 36:2; [M-H]-@7.03	ME183198	1.04	0.25	1.28	1.15
PC 33:1; [M-Ac-H]-@6.73	ME183157	1.05	0.32	1.19	1.24
PI 38:3; [M-H]-@6.01	ME183237	1.02	0.34	1.21	1.21
PC 35:1; [M-Ac-H]-@7.36	ME183165	1.17	0.22	1.20	1.21
plasmenyl-PE 38:6; [M-H]-@6.61	ME183264	1.12	0.19	1.26	1.17

Factors:

F1	Disease:AS-Control-P \| Matrix:Plasma \| Sample type:Plasma
F2	Disease:AS-Control-S \| Matrix:SRF \| Sample type:Fluids and Secretions
F3	Disease:Coats \| Matrix:CB \| Sample type:Fluids and Secretions
F4	Disease:JB-Coats-P \| Matrix:Plasma \| Sample type:Plasma

Data matrix